Inclusion Criteria:

- Eligible patients will have clinical stage T1c, T2a, or T2b, a pre-biopsy PSA level
<10 ng/mL and a biopsy Gleason score of 3+3 (or 3+4 if fewer than 30% of biopsy cores
are involved).

- The ability to understand and willingness to sign a written informed consent are
necessary.

Exclusion Criteria:

- Patients with tumor parameters that fall outside of the inclusion criteria.

- Patients with evidence on imagining (bone scan, CT, or MRI) suggestive of
disseminated disease.

- Patients who have had any form of prior prostate treatment (surgery, radiotherapy,
cryotherapy, high intensity focused ultrasound, TURP).

- A prior course of hormone therapy (androgen deprivation) of greater than 3 months
duration.

- The use of other concurrent investigational agents.

- There are no exclusions due to co-morbid disease or illnesses except for patients
with severe inflammatory bowel disease.

- No life expectancy restrictions will apply.

- Performance status will not be considered.